SETD7 is altered in 0.19% of all cancers with diffuse large B-cell lymphoma, not otherwise specified, follicular lymphoma, B-cell lymphoblastic leukemia/lymphoma, mantle cell lymphoma, and T-cell lymphoblastic leukemia/lymphoma having the greatest prevalence of alterations .
The most common alterations in SETD7 are SETD7 Amplification (0.07%), SETD7 Mutation (0.07%), SETD7 Loss (0.05%), SETD7 T75S (0.05%), and SETD7 D88H (0.02%) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.